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Introduction
Graft-versus-host-disease (GVHD) is the most common and life-threatening complication after allogeneic stem cell transplantation (allo-SCT).
1,2 B-cell depletion with rituximab (RTX) has been successful in steroid-refractory chronic GVHD, showing response rates of 43-80%. [3] [4] [5] [6] [7] [8] However, the nature of B-cell contribution, as well as to what extent B-cell depletion can restore physiological conditions, has so far not been clarified. Hypotheses obtained from mouse models of chronic GVHD and retrospective analysis of patient materials have been conflicting. For example, a correlation was found between high levels of B-cell activating factor (BAFF) in a retrospective analysis of 45 patients with active chronic GVHD. 9 However, no significant correlation could be found between the levels of BAFF and RTX-responsiveness in the most recently published prospective phase II study of 37 patients. 10 In active chronic GVHD prior to response to immunosuppressants, expansion of activated CD27 + B cells has been observed. 9 Another retrospective study of 35 patients suffering from active chronic GVHD, in which treatment included prednisone and calcineurin inhibitors, showed significantly lower numbers of memory B cells (CD27 + ). 11 To our knowledge, no prospective comparisons have been made between immune subsets before and after B-cell depletion therapy of steroid-refractory chronic GVHD, so details on reestablishment of normal B-cell pools after RTX treatment, as well as changes in immune-pathology of the skin, still have to be clarified. Consequently, the aim of this study was to demonstrate effectiveness of B-cell depletion therapy in steroid-refractory chronic GVHD and to identify potentially involved cell subsets by a comprehensive immunological analysis in a prospective clinical trial.
Design and Methods

Patients and patient material
In the course of a prospective study (Eudra-CT 2008-004125-42), a cohort of 20 chronic GVHD patients who received allo-SCT due to various hematologic malignancies was treated with 4 weekly doses of 375 mg/m 2 RTX (F. Hoffmann-La Roche Ltd., Basel, Switzerland). All patients had chronic GVHD with at least skin symptoms. Inclusion criteria were age over 18 years, life-expectancy of more than six months, and a World Health Organization (WHO)
The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study Suzanne and February 2010 according to clinical protocols approved by the local ethics board. In cases of progression or recurrence of chronic GVHD, for which an alternative systemic therapy was needed, patients were excluded from the study and follow up was ended. Response criteria were set as the following: complete response (CR) and partial response (PR) defined according to the recently published National Institutes of Health (NIH) criteria. 12 For laboratory analysis, blood samples were taken from each patient before and after treatment, and consecutively every two months until one year after treatment. Peripheral blood mononuclear cells (PBMCs) were immediately isolated and lymphocyte numbers measured by TruCount (according to the manufacturer's protocol, BD Biosciences). PBMCs were then frozen and stored in liquid nitrogen until further analysis. Plasma and serum were stored at -80°C until further analysis. Furthermore PBMC, plasma and serum samples from allo-SCT recipients without GVHD (No-GVHD) and healthy donors were obtained. An informed consent was obtained for other control samples to be used for analysis. Skin biopsies were obtained before RTX therapy and five months after treatment from adjacent sites if possible, otherwise from the most active site, and stored in 4% formalin and embedded in paraffin. Eye involvement was measured before RTX, three and seven months after treatment, using a Schirmer's test.
FACS staining, cytokine analysis, 13 B-cell clonality, chimerism, 14 and auto-antibodies, 15 histological stainings 3 and the control groups used are described in the Online Supplementary Design and Methods section and Online Supplementary Tables S1 and S2.
Statistical analysis
For prospective data analysis of the cohort of 20 patients SPSS (IBM, Chicago, USA) was used. Receiver operating characteristic (ROC) curve was used to determine a cut-off point for B-cell numbers that was predictive for responsiveness to treatment. Hazard ratios were calculated using a Cox's regression analysis. Incidence of response was calculated using the Kaplan-Meier method. A Kaplan-Meier curve was used to illustrate responsiveness and a log rank test was used to compare incidence between patients with high and low B-cell numbers. Data from FACS staining, plasma and serum analysis were analyzed using GraphPad Prism 5 for Windows (GraphPad Software, La Jolla, USA). Differences in lymphocyte subsets were compared using two-way ANOVA for normally distributed data. Gaussian-distributed groups were compared using Student's t-test. Groups of data which were not normally distributed were compared using Mann-Whitney U tests. In either case, a probability level of 5% (P<0.05) was found to be significant.
Results and Discussion
In order to prospectively test clinical efficacy of B-cell depletion therapy in steroid-refractory chronic GVHD, a cohort of 20 patients presenting with at least skin involvement was treated with rituximab and followed until one year after treatment or until relapse of chronic GVHD. Two patients had to be excluded from further study; one due to an allergic reaction to rituximab and one due to relapse of leukemia. Eighteen patients could, therefore, be included for further analyses. Patients' characteristics are shown in the Online Supplementary Table S3 . Overall response rate was 61% (n=11). Only partial responses were seen during the time of follow up. Median time to response was three months (range 1-4 months) and 55% of responders had an ongoing response (n=6). Median response duration, measured until last time of follow up, was 12 months (range 1-12 months) ( Table 1) . Dosage of prednisone could be reduced in 50% of patients (n=9) and completely stopped in 4 patients (22%). Median time to dose reduction of prednisone was three months (range 1-7 months) ( Table 1) .
To investigate whether the production of auto-antibod- ies was associated with symptoms of chronic GVHD as reported, 16, 17 serum before and after rituximab treatment of patients and No-GVHD controls was tested for a panel of antibodies correlated with Systemic Sclerosis (SSc) in terms of quality (type) and quantity. Several auto-antibodies were found in serum of both responders and nonresponders, as well as in serum of No-GVHD controls. However, no significant associations between presence of antibodies and chronic GVHD could be found (data not shown) as also reported by others. 18 Conflicting data have also been reported on the correlation between BAFF-levels or BAFF-to-B-cell ratios in RTX-responding patients, as the recently published prospective study of 37 patients 10 did not show a significant correlation in contrast to a ret-
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haematologica | 2011; 96(9) rospective study of 20 patients. 19 Also, our prospective study of 18 patients did not show any correlation between BAFF-levels and RTX-response. However, differences in these studies and our data could also be partially a consequence of the fact that patients received different doses of corticosteroids in different studies, and high doses of corticosteroids as used in our study have been reported to partially inhibit BAFF. 20 In our study, only IL-21 was significantly decreased in responding as compared to non-responding patients (data not shown).
Peripheral blood mononuclear cells from different groups were analyzed by flow cytometry for lymphocyte subsets, and there was no significant difference in total lymphocyte numbers between patient groups, No-GVHD and healthy donor controls. No significant differences were observed between responders and non-responders when comparing CD8 + and CD4 + T cells in the peripheral blood. Also (Table 2) . Rituximab sufficiently depleted all B cells in the peripheral blood of all patients as indicated by the lack of CD19-positive cells at one month after the first rituximab dose (T=1; data not shown). B-cell reconstitution in peripheral blood could only be observed 10-12 months after start of rituximab. The MFI of CD5 + B cells was significantly decreased in responding patients before treatment (T=0) and normalized until T=12 (P<0.05), and was, therefore, then again comparable to all controls. These differential expression patterns of CD5 in patients and all controls are shown in representative dot plots in Figure1B. At T=12, also CD5-B-cell numbers, naive B-cell numbers, and HLA-DRhigh B-cell numbers in responding patients were again comparable to all controls, thus with a significant difference when compared to T=0 (P<0.05). Knowledge about CD5 and its signaling functions in lymphocytes is still very limited and the biological role of CD5-and CD5+ B cells differ in mice and men. 21, 22 In contrast to our study, an increase in CD5+ B cells has been observed in patients with other autoimmune disease such as lupus erythematosus. 22 However, regardless of its function, loss of CD5 expression on B cells might assist in identifying patients who will benefit from B-cell depletion.
To investigate whether responding and non-responding patients also show differences in infiltrating immune cells of the skin, skin sections of responders, non-responders, and healthy donors were additionally stained for T-and B-cell markers. As reported, 23 only minimal immune cell infiltrates could be observed in patients with chronic GVHD: total numbers of T cells were within the range of T-cell infiltrates usually observed in healthy individuals (data not shown). However, the percentage of skin-infiltrating CD8 + T cells was significantly higher when compared to healthy controls (P<0.05; Figure 1C) . No significant difference was observed in skin infiltrating T cells before rituximab treatment between responding and non-responding patients (data not shown). There was no difference in numbers of skin infiltrating B cells between responding and non-responding patients, and B cells disappeared after rituximab treatment (data not shown). After rituximab treatment, only ongoing responding patients were analyzed at five months after study entry as non-responding patients had already undergone other therapies and were thus no longer eligible. A significant decrease in CD8 + T cells was observed after five months in responding patients (P<0.01), whereas there was no significant change in CD4 + T-cell numbers ( Figure 1C and D) . This resulted again in normalization of the percentage of skininfiltrating CD8 + T cells when compared to the healthy control group ( Figure 1C ). This suggests that B-cell depletion by rituximab not only reduces the number of potentially antigen-presenting B cells, but also reduces the skin infiltrating CD8 + T-cell compartment. This, therefore, supports recent hypotheses of a T-cell to B-cell crosstalk in the setting of chronic graft-versus-host disease in man. 18 In summary, to our knowledge this is the first prospective comprehensive study which describes the immunological phenotype of RTX-sensitive as compared to RTXunresponsive chronic graft-versus-host disease in the peripheral blood and the skin. Elevation of B-cell numbers with a dominant naïve, antigen-presenting phenotype, as well as skewing towards CD5-B cells and B cells with a low CD5 expression was selectively found in responding patients and was the only predictive factor of responsiveness to rituximab. Physiological B-cell homeostasis was re-established in responding patients one year after treatment and associated with a reduced skin infiltration of CD8 + T cells in responding patients. This suggests that an imbalanced B-cell repertoire can contribute to chronic graft-versus-host disease by sustaining skin-infiltrating CD8 + T cells. These findings could also be useful in identifying in advance those patients who will benefit from rituximab treatment and provide a basis for larger confirmatory prospective clinical trials. 
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